Abiraterone Acetate - CAS 154229-18-2
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Abiraterone Acetate
Catalog Number:
B0084-461965
Synonyms:
CB7630; Zytiga; CB-7630; CB7630; Abiraterone (acetate)
CAS Number:
154229-18-2
Description:
The acetate form of abiraterone, which blocks the synthesis of androgens by inhibiting CYP17A1.
Molecular Weight:
391.55
Molecular Formula:
C26H33NO2
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C
InChI:
InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1
InChIKey:
UVIQSJCZCSLXRZ-UBUQANBQSA-N
Targets:
Cytochrome P450
Catalog Number Size Price Stock Quantity
B0084-461965 10 g $298 In stock
Bulk Inquiry
Chemical Structure
CAS 154229-18-2 Abiraterone Acetate

Related Cytochrome P450 Products


CAS 870093-23-5 Talarozole

Talarozole
(CAS: 870093-23-5)

Talarozole, a retinoic acid metabolism blocking agent (RAMBA), is a potent and selective inhibitor of cytochrome P450 26 to treat dermatalogical diseases includ...

VT-464 racemate
(CAS: 1375603-36-3)

The racemate form of VT-464, a non-steroidal compound, has been found to lead to the reduction of androgen through acting as a human CYP17 lyase inhibitor. IC50...

CAS 566939-85-3 Orteronel

Orteronel
(CAS: 566939-85-3)

Orterone (TAK-700) is an orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrog...

CAS 298-81-7 Methoxsalen

Methoxsalen
(CAS: 298-81-7)

Methoxsalen — also called xanthotoxin, marketed under the trade names Oxsoralen, Deltasoralen, Meladinine — is a drug used to treat psoriasis, eczema, vitiligo,...

UK 39671
(CAS: 85473-17-2)

UK 39671 is a cytochrome P-450 inhibitor

CAS 50-52-2 Thioridazine

Thioridazine
(CAS: 50-52-2)

Thioridazine is an inhibitor of CYP1A2 and CYP3A2. It is a piperidine typical antipsychotic drug belonging to the phenothiazine drug group and was previously wi...

VT-464 R enantiomer
(CAS: 1375603-38-5)

The R-enantiomer form of VT-464, a non-steroidal compound, has been found to lead to the reduction of androgen through acting as a human CYP17 lyase inhibitor.

CFG920
(CAS: 1260006-20-9)

CFG920 is a Steroid 17-alpha-hydroxylase inhibitor originated by Novartis. It has potential antiandrogen and antineoplastic activities. It may inhibit cell prol...

CAS 1004316-88-4 Cobicistat

Cobicistat
(CAS: 1004316-88-4)

Cobicistat is a potent inhibitor of cytochrome P450 3A enzymes, including the important CYP3A4 subtype. It also inhibits intestinal transport proteins, increasi...

CAS 10236-47-2 Naringin

Naringin
(CAS: 10236-47-2)

Naringin inhibits hepatic P-glycoprotein (P-gp) and some drug-metabolizing cytochrome P450 enzymes, including CYP3A4 and CYP1A2, which may result in drug-drug i...

CAS 56-54-2 Conquinine

Conquinine
(CAS: 56-54-2)

Conquinine is a Cytochrome P450 2D6 inhibitor. It is a dextrorotatory stereoisomer of quinine extracted from the bark of the Cinchona tree and similar plant spe...

CAS 154229-19-3 Abiraterone

Abiraterone
(CAS: 154229-19-3)

Abiraterone blocks the synthesis of androgens by inhibiting CYP17A1. It is used to treat metastatic, castration-resistant prostate cancer.

VT-464
(CAS: 1610537-15-9)

VT-464, also called as Seviteronel, is an oral, non-steroidal, lyase-selective CYP17 inhibitor to reach Phase II clinical trials in Breast cancer in USA (PO). i...

BMS-351
(CAS: 1370001-71-0)

BMS-351 is a selective and nonsteroidal CYP17A1 lyase inhibitor with good selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 has become a preclinical ca...

CAS 62-68-0 Proadifen Hydrochloride

Proadifen Hydrochloride
(CAS: 62-68-0)

Proadifen hydrochloride is a Cytochrome P450 inhibitor (IC50 = 19μM) and stimulate endothelial cell prostacyclin production.

Dafadine-A
(CAS: 1065506-69-5)

Dafadine-A, the first identified chemical inhibitor of DAF-9, could restrain the dauer formation, developmental timing and longevity in the nematodeCaenorhabdit...

CAS 117620-77-6 3-Cyano-7-ethoxycoumarin

3-Cyano-7-ethoxycoumarin
(CAS: 117620-77-6)

3-Cyano-7-ethoxycoumarin, a kind of fluorogenic coumarin ether, is a fluorescent p450 substrate and used to confirm the effect of sorts of CYP450 enzymes.

CAS 120511-73-1 Anastrozole

Anastrozole
(CAS: 120511-73-1)

Anastrozole is an aromatase inhibitor that acts via binding competitively to the hem group of the CYP unit of the enzyme thereby reducing estrogen biosynthesis ...

CAS 851983-85-2 Galeterone

Galeterone
(CAS: 851983-85-2)

Galeterone (TOK-001 or VN/124-1) is a novel antiandrogen under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique ...

VT-1161
(CAS: 1340593-59-0)

VT-1161 is a 14-alpha demethylase inhibitor as a tetrazole antifungal agent originated by Viamet Pharmaceuticals. VT-1161 shows potent efficacy in treatment of ...

Reference Reading


1.Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden.
Svensson J1, Andersson E1, Persson U1, Edekling T2, Ovanfors A3, Ahlgren G4. Scand J Urol. 2016 Apr 25:1-6. [Epub ahead of print]
OBJECTIVE: In a randomized clinical trial (COU-AA-301), abiraterone acetate (Zytiga®) was shown to be superior to prednisone in the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, the value of abiraterone treatment for patients with mCRPC in clinical practice in Sweden is not known. The aim of this study was to compare the outcomes and treatment patterns of abiraterone treatment in a Swedish observational study to those of the pivotal clinical trial, thereby discussing the external validity of the postchemotherapy clinical trial from a Swedish perspective.
2.Development and Validation of a Novel LC-MS/MS Method for Simultaneous Determination of Abiraterone and Its Seven Metabolites in Human Serum: Innovation in Separation of Diastereoisomers Without Use of a Chiral Column.
Alyamani M1, Li Z2, Upadhyay SK3, Anderson D4, Auchus RJ3, Sharifi N5. J Steroid Biochem Mol Biol. 2016 Apr 7. pii: S0960-0760(16)30098-X. doi: 10.1016/j.jsbmb.2016.04.002. [Epub ahead of print]
Abiraterone acetate (AA), the prodrug of abiraterone, is FDA-approved for the treatment of castration-resistant prostate cancer. Abiraterone is metabolized in patients to a more potent analogue, D4A. However, we have recently reported that this analogue is further metabolized to additional metabolites in patients treated with AA. Here, we present a liquid chromatography-tandem mass spectrometry method developed to resolve and detect abiraterone and its seven metabolites in human serum using an AB Sciex Qtrap 5500 mass analyzer coupled with a Shimadzu Nexera UPLC station. Analytes and the internal standard (abiraterone-d4) were extracted from human serum using the liquid-liquid extraction procedure. The analytes were separated using a Zorbax Eclipse Plus C18 150×2.1mm, 3.5μm column at 40°C and an isocratic mobile phase 35% A (0.1% formic acid in water), 65% B (0.1% formic acid in methanol:acetonitrile; 60:40). Electrospray ionization in positive mode was applied with multiple reaction monitoring in a total run time of 13minutes.
3.The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man.
Geboers S1, Stappaerts J1, Mols R1, Snoeys J2, Tack J3, Annaert P1, Augustijns P4. J Pharm Sci. 2016 Apr 6. pii: S0022-3549(16)00436-6. doi: 10.1016/j.xphs.2016.03.008. [Epub ahead of print]
To relate the reported positive effect of food on the oral bioavailability of abiraterone to the intraluminal behavior of abiraterone acetate, an in vivo experiment was performed, in which duodenal fluids and plasma samples were collected from healthy volunteers after the administration of abiraterone acetate in fasted and postprandial conditions. The plasma concentration-time profiles confirmed the positive food effect. Nevertheless, intraduodenal concentrations of abiraterone acetate and abiraterone did not fully reflect this observation. This apparent discrepancy was explored by performing several in vitro experiments including solubility, dissolution, and transfer studies. Gastrointestinal transfer studies illustrated a positive impact of gastric processing of the abiraterone acetate formulation on the duodenal concentrations in the fasted state, which could not be observed in the postprandial condition. As the influence of gastric dissolution on the intraluminal concentrations in the small intestine declines aborally, it is most likely the superior solubility of abiraterone acetate and abiraterone in intestinal fluids of the fed state which dictates the food effect.
4.A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Bonnefoi H1, Grellety T2, Tredan O3, Saghatchian M4, Dalenc F5, Mailliez A6, L'Haridon T7, Cottu P8, Abadie-Lacourtoisie S9, You B10, Mousseau M11, Dauba J12, Del Piano F13, Desmoulins I14, Coussy F15, Madranges N2, Grenier J16, Bidard FC8, Proudhon C8, M Ann Oncol. 2016 May;27(5):812-8. doi: 10.1093/annonc/mdw067. Epub 2016 Feb 18.
BACKGROUND: Several expression array studies identified molecular apocrine breast cancer (BC) as a subtype that expresses androgen receptor (AR) but not estrogen receptor α. We carried out a multicentre single-arm phase II trial in women with AR-positive, estrogen, progesterone receptor and HER2-negative (triple-negative) metastatic or inoperable locally advanced BC to assess the efficacy and safety of abiraterone acetate (AA) plus prednisone.